** Brokerage UBS cuts PT on drugmaker Regeneron Pharmaceuticals REGN.O to $560 from $633
** UBS says it has removed smoker's lung drug, itepekimab, from "current collaboration pipeline given the regulatory uncertainty and potential competitor entries"
** Company and partner Sanofi SASY.PA said last week that their experimental drug, itepekimab, failed in a late-stage trial, testing it for a lung disease commonly called "smoker's lung", but met the goal of another trial for the same disease
** UBS says REGN will have higher operating expenses in the near-to-mid term due to integrating 23andMe and increased R&D for obesity treatments
** However, UBS expects these costs to decrease after 2030
** "Eylea franchise weakness remains a key overhang for our near-term REGN thesis" - UBS
** Including session's move, REGN down 31.8% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.